

**Table S16.**

Panel of AML cell lines with mutation information and sensitivity data for Cabozantinib, Crenolanib, and Quizartinib measured by an MTS-assay. Number in brackets gives EC<sub>50</sub> for Cabozantinib in the respective cell line.

<i>Cell line</i>	<i>Described mutations</i>	<i>FLT3 inhibitor sensitivity</i>	<i>FLT3 expression</i>
<i>THP-1</i>	NRAS, MLL-AF9	no	yes
<i>OCI-AML3</i>	NPM1, DNMT3A	no	yes
<i>OCI-AML5</i>		no	yes
<i>U-937</i>		no	no
<i>KG-1a</i>	OP1-FGFR1	no	no
<i>NB-4</i>	PML-RARA	no	no
<i>HL-60</i>	NRAS	no	no
<i>SD-1</i>	BCR-ABL	no	no
<i>K-562</i>	BCR-ABL	no	no
<i>MV-4-11</i>	FLT3-ITD (homozygous), MLL-AF9	yes (16 nM)	yes
<i>MOLM-13</i>	FLT3-ITD (heterozygous), MLL-AF9	yes (73 nM)	yes
<i>MONO-MAC-1</i>	FLT3 V592A, MLL-AF9	yes (34 nM)	yes
<i>MONO-MAC-6</i>	FLT3 V592A, MLL-AF9	yes (288 nM)	yes
<i>EOL-1</i>	FIP1L1-PDGFRα	yes (1 nM)	yes
<i>KASUMI-1</i>	KIT N822K, KRAS, AML-ETO	yes (69 nM)	no